Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines.
Newleos Therapeutics has raised $93.5M in total funding. The most recent round was Series A. The last funding was announced in February 2025.
Newleos Therapeutics's investors include Novo Holdings, DCVC Bio, Longwood Fund, Goldman Sachs Alternatives, Arkin Bio Ventures.
Newleos Therapeutics is headquartered in Boston, United States.
Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines.
Newleos Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Newleos Therapeutics — Funding & Investors." VCBacked, February 13, 2025, https://www.vcbacked.co/company/newleos-therapeutics. Accessed July 19, 2026.
VCBacked. (2025). Newleos Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/newleos-therapeutics
{{cite web |title=Newleos Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/newleos-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated